Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation  Marcos de Lima, David L. Porter, Minoo Battiwalla, Michael R. Bishop, Sergio A. Giralt, Nancy M. Hardy, Nicolaus Kröger, Alan S. Wayne, Christoph Schmid  Biology of Blood and Marrow Transplantation  Volume 20, Issue 1, Pages 4-13 (January 2014) DOI: 10.1016/j.bbmt.2013.08.012 Copyright © 2014 Terms and Conditions

Figure 1 Donor–cell consolidation of remission for AML relapse after AlloSCT. Analysis of European Bone Marrow Transplantation Registry data from 38 patients in CR after first-line cytoreductive therapy for relapsed AML after AlloSCT demonstrated improved OS with use of donor cells for consolidation: 55% ± 11% vs. 20% ± 10% (P = .038). DLI and second AlloSCT were considered as time-dependent variables. Adapted from [30]. Biology of Blood and Marrow Transplantation 2014 20, 4-13DOI: (10.1016/j.bbmt.2013.08.012) Copyright © 2014 Terms and Conditions

Figure 2 Theoretical relative therapeutic potential of cellular therapies for relapse. The shaded quadrant represents the zone of optimal specificity with respect to tumor versus off-target cytotoxic tissue damage, which maximizes antitumor potency and minimizes cell-mediated morbidity. Conventional DLI and second AlloSCT (depicted in red) are the currently available cell-based treatments for relapse, against which novel therapies (blue) will be judged. TAA, tumor-associated antigen; MiAg, minor histocompatibility antigen. Biology of Blood and Marrow Transplantation 2014 20, 4-13DOI: (10.1016/j.bbmt.2013.08.012) Copyright © 2014 Terms and Conditions